Eli Lilly announced that its obesity drug Zepbound (tirzepatide) significantly reduced the risk of heart complications and improved symptoms in patients with heart failure with preserved ejection fraction (HFpEF) and obesity. In a Phase 3 trial, the drug lowered the risk of hospitalization or worsening heart failure by 38% over two years compared to a placebo. These results position Zepbound as the second GLP-1-based therapy to demonstrate cardiovascular benefits in this specific patient population.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.